AMAL Therapeutics to publish R&D outcomes in Cancers

Geneva, Switzerland, February 17, 2021 – AMAL Therapeutics announced today that its recent research findings, in collaboration with Fox Chase Cancer Center, about a novel protein‐based vaccine against self‐antigen reducing the formation of sporadic colon adenomas in mice, is on line on the Cancers website. The publication demonstrate Ascl2 as a promising target for immunoprevention for individuals at elevated risk of developing colorectal cancer.

Share this entry

You are now leaving our website

Using this link will let you leave a website of Amal Therapeutics or to a different domain under the control of Amal Therapeutics. In the event that the linked site is not under the control of Amal Therapeutics but under the control of a third party or an affiliate in the Boehringer Ingelheim group of companies, Amal Therapeutics shall not be responsible for the contents, processing of personal data of any linked site or any link contained in a linked site, or any changes or updates to such sites.

This link is provided to you only as a convenience, and the inclusion of any link does not imply endorsement by Amal Therapeutics of the site.

Target URL: